Wild-Type Phosphoribosylpyrophosphate Synthase (PRS) from Mycobacterium tuberculosis: A Bacterial Class II PRS? by Breda, Ardala et al.
Wild-Type Phosphoribosylpyrophosphate Synthase (PRS)
from Mycobacterium tuberculosis: A Bacterial Class II
PRS?
Ardala Breda
1,2, Leonardo K. B. Martinelli
1,2, Cristiano V. Bizarro
1, Leonardo A. Rosado
1,2,
Caroline B. Borges
1,2, Dio ´genes S. Santos
1,2*, Luiz A. Basso
1,2*
1Instituto Nacional de Cie ˆncia e Tecnologia em Tuberculose (INCT-TB), Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Programa de Po ´s-Graduac ¸a ˜oe m
Biologia Celular e Molecular, Pontifı ´cia Universidade Cato ´lica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil, 2Programa de Po ´s-Graduac ¸a ˜oe m
Biologia Celular e Molecular, Pontifı ´cia Universidade Cato ´lica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil
Abstract
The 5-phospho-a-D-ribose 1-diphosphate (PRPP) metabolite plays essential roles in several biosynthetic pathways, including
histidine, tryptophan, nucleotides, and, in mycobacteria, cell wall precursors. PRPP is synthesized from a-D-ribose 5-
phosphate (R5P) and ATP by the Mycobacterium tuberculosis prsA gene product, phosphoribosylpyrophosphate synthase
(MtPRS). Here, we report amplification, cloning, expression and purification of wild-type MtPRS. Glutaraldehyde cross-linking
results suggest that MtPRS predominates as a hexamer, presenting varied oligomeric states due to distinct ligand binding.
MtPRS activity measurements were carried out by a novel coupled continuous spectrophotometric assay. MtPRS enzyme
activity could be detected in the absence of Pi. ADP, GDP and UMP inhibit MtPRS activity. Steady-state kinetics results
indicate that MtPRS has broad substrate specificity, being able to accept ATP, GTP, CTP, and UTP as diphosphoryl group
donors. Fluorescence spectroscopy data suggest that the enzyme mechanism for purine diphosphoryl donors follows a
random order of substrate addition, and for pyrimidine diphosphoryl donors follows an ordered mechanism of substrate
addition in which R5P binds first to free enzyme. An ordered mechanism for product dissociation is followed by MtPRS, in
which PRPP is the first product to be released followed by the nucleoside monophosphate products to yield free enzyme for
the next round of catalysis. The broad specificity for diphosphoryl group donors and detection of enzyme activity in the
absence of Pi would suggest that MtPRS belongs to Class II PRS proteins. On the other hand, the hexameric quaternary
structure and allosteric ADP inhibition would place MtPRS in Class I PRSs. Further data are needed to classify MtPRS as
belonging to a particular family of PRS proteins. The data here presented should help augment our understanding of MtPRS
mode of action. Current efforts are toward experimental structure determination of MtPRS to provide a solid foundation for
the rational design of specific inhibitors of this enzyme.
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Introduction
Tuberculosis (TB) is a chronic infectious disease caused mainly
by Mycobacterium tuberculosis, being the second leading cause of
mortality by infectious diseases in human populations, killing
about 1.7 million people worldwide in 2009 [1]. One third of the
world population is estimated to be infected with latent TB. The
latter is worsened by the spread of HIV-TB co-infection, which
can lead to increased rates of TB reactivation, being up to 30% of
deaths among HIV positive subjects caused by the TB bacilli [2].
TB infection is treated by a combination of four drugs that act
upon different molecular targets [3]. The treatment regimen
includes six month therapy with rifampicin and isoniazid,
supplemented with pyrazinamide and ethambutol in the first two
months [1]. In recent years, M. tuberculosis isolates resistant to one
or more of these drugs have been spreading, which seriously
hampers the success of measures to control TB [4]. The increasing
incidence of TB has been paralleled by a rapid increase of cases
caused by multi-drug resistant (MDR-TB) and extensively-drug
resistant M. tuberculosis strains (XDR-TB), with estimated cases and
annual deaths worldwide of, respectively, of 0.5 million and
100,000 for MDR-TB, and 35,000 and 20,000 for XDR-TB [5,6].
Recently, TB infection with totally resistant strains (TDR-TB),
which are resistant to all first and second line classes of anti-TB
drugs tested, have been isolated in Iran and India [7,8]. There is
an urgent need to develop new therapeutic strategies to combat
TB. Strategies based on the selection of new targets for
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39245antimycobacterial agent development include elucidation of the
role played by proteins from biochemical pathways that are
essential for mycobacterial growth [9].
Phosphoribosylpyrophosphate synthase (PRS; EC 2.7.6.1) plays
central roles in a number of cellular processes, catalyzing the
synthesis of 5-phospho-a-D-ribose 1-diphosphate (PRPP; a-D-5-
phosphoribosylpyrophosphate; a-D-ribosyl diphosphate 5-phos-
phate). PRS enzymes catalyze, in the presence of Mg
2+, the
transfer of b,c-diphosphoryl moiety of adenosine 59-triphosphate
(ATP) to C1-hydroxyl group of a-D-ribose 5-phosphate (R5P),
yielding PRPP [10,11] (Figure 1). PRPP is an essential metabolite
for a number of distinct biochemical pathways including de novo
and salvage pathways of purine and pyrimidine nucleotide
synthesis, and biosynthesis of NAD, histidine and tryptophan
[12–14]. PRPP is also associated with cell integrity in Saccharomyces
cerevisiae [15]. The yeast genome encodes five distinct prs genes,
whose products are combined to form hetero-oligomeric catalytic
active PRS, with possible role in plasma membrane stability [16].
In Corynebacteriaceae, such as mycobacteria, PRPP is a co-
substrate for the synthesis of polyprenylphosphate-pentoses, which
are the source of arabinosyl residues of arabinogalactan, compo-
nent of the mycobacterial cell wall, and lipoarabinomannan, a
highly immunogenic lipoglycan that is involved in modulating the
host immune response [17,18].
PRS enzymes usually require Mg
2+NATP as diphosphoryl group
donor. The PRS proteins from Escherichia coli [19], Salmonella
typhimurium [20] and mammals [21] have been shown to also
require a second free Mg
2+ ion for increased catalytic rates. PRS
enzymes from these organisms, as well as from Bacillus subtilis [22],
are representative of Class I (also known as ‘‘Classical’’) PRS
proteins, with hexameric quaternary structure, allosteric inhibition
by purines ribonucleoside diphosphate (adenosine 59-diphosphate,
ADP; and guanosine 59-diphosphate, GDP), specificity for ATP (or
dATP) as diphosphoryl group donor, and requirement of
inorganic phosphate (Pi) for enzyme activity [23]. The three-
dimensional structures of PRS enzymes from B. subtilis (PDB ID:
1IBS) [21] and Homo sapiens (PDB ID: 2H06) [11] demonstrate that
the functional enzyme is a hexamer of identical subunits,
associated two by two, where each monomer is composed by
two domains, both with high topological similarity to the type I
family of phosphoribosyltransferases [24]. In addition, there is
conservation of amino acid residues in the PRPP substrate binding
site [22]. Class II PRS proteins share several structural charac-
teristics with Class I enzymes. However, Class II PRSs are
characterized by not being dependent on Pi for activity, have
Figure 1. Chemical reaction catalyzed by MtPRS (Rv1017c). This figure also shows the metabolic source of R5P and the biosynthetic pathways
in which the reaction product PRPP plays central roles.
doi:10.1371/journal.pone.0039245.g001
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triphosphate, GTP; cytosine 59-triphosphate, CTP; and uridine 59-
triphosphate, UTP), and are not allosteric inhibited by purines
ribonucleosides diphosphate [23,25]. Class II PRS proteins appear
to be specific for plants as they have been identified in spinach [26]
and Arabidopsis thaliana isozymes 3 and 4 [27]. Nevertheless the
PRS enzyme from pathogenic Gram negative enterobacteria S.
typhimurium was reported as using GTP, ITP, CTP and UTP in
addition to ATP as substrate [28]. More recently, a PRS enzyme
from the archeon Methanocaldococcus jannaschii has been shown to be
tetrameric (PDB ID: 1U9Y), activated by Pi, non-allosteric
inhibited by ADP, and that employs ATP as diphosphate donor
[25]. These findings prompted the proposal that M. jannaschii PRS
belongs to a new Class III of PRPP synthases [25].
Here we describe cloning of prsA (Rv1017c) from M. tuberculosis;
and expression, purification, molecular and kinetic characteriza-
tion of the non-tagged recombinant PRS (MtPRS). Glutaralde-
hyde cross-linking results indicate that the oligomeric state of
MtPRS is predominantly hexameric in solution. However, the
presence of ligands appears to stabilize alternative oligomeric
states. MtPRS activity was assessed by a novel coupled continuous
spectrophotometric assay that measures the decrease in orotate
concentration catalyzed by M. tuberculosis orotate phosphoribosyl-
transferase (MtOPRT) due to PRPP formation by recombinant
MtPRS enzyme activity. Steady-state data indicate that MtPRS
can use both pyrimidine and purine nucleosides triphosphate as
diphosphoryl group donors (broad specificity). In addition, enzyme
activity measurements show that MtPRS is catalytically competent
in the absence of Pi. These data suggest that MtPRS belongs to
Class II PRS family, as plant homologues, even though the
primary amino acid structure is indicative of structural resem-
blance to Class I PRS. Equilibrium binding data are also presented
suggesting that MtPRS mechanism is likely random order of
substrate addition for purine diphosphoryl donors and ordered
addition of pyrimidine diphosphoryl donors, with ordered release
of products in which PRPP dissociation is followed by the purine
or pyrimidine nucleoside monophosphate products. The prsA-
encoded protein has been predicted to be essential for in vitro
growth of M. tuberculosis based on transposon-site hybridization
studies [29]. More recently, PRS from Corynebacterium glutamicum,a
model organism used to study M. tuberculosis cell physiology, has
been shown to be essential for the maintenance of cellular integrity
[30]. The results presented here are discussed in light of previous
reports on MtPRS [30,31], and should thus contribute to a better
understanding of MtPRS mode of action.
Methods
Gene Amplification
The prsA gene (Rv1017c) was PCR amplified from total
genomic DNA of M. tuberculosis H37Rv strain using specific
primers designed to contain NdeI (primer sense 59GCCATAT-
GAGCCACGACTGGACCGATAATCG39) and BamHI (primer
antisense 59GCGGATCCTCATGCGTCCCCGTC-
GAAAAGT39) restriction sites (underlined). An internal restriction
site for NdeI was removed from the gene sequence by site-directed
mutagenesis at codon position 170, in which a thymine was
replaced with a cytosine at codon’s third position (CAT to CAC),
resulting in a sense mutation that maintained a histidine amino
acid at this position. Dimethyl sulfoxide (DMSO) was added to the
PCR reaction at final concentration of 10%. Amplified prsA gene
was cloned into pET-23a(+) expression vector (Novagen). The
integrity of constructs was confirmed in all cases by appropriate
selections and digests with restriction enzymes (New England
Biolabs). Inserted sequences were confirmed by automated DNA
sequencing.
Expression and Purification of Recombinant MtPRS
Competent E. coli BL21(DE3) (Novagen) cells were electropo-
rated with pET-23a(+)::prsA recombinant vector and selected on
Luria-Bertani (LB) agar plates containing 50 mgm L
21 ampicillin.
Aliquots of a 5 mL cell culture grown from a single colony were
used to inoculate 500 mL of Terrific Broth (TB) medium
supplemented with 50 mgm L
21 ampicillin, grown at 37uC and
180 rpm to an optical density (OD600 nm) of 0.4–0.6. At this
growth stage, culture temperature was lowered to 30uC and
protein expression was carried out without isopropyl-b-D-
thiogalactopyranoside (IPTG) induction, for 24 hours. Cells were
harvested by centrifugation (11,800 g) for 30 min at 4uC and
stored at 220uC. Protein purification was performed by Fast-
Performance Liquid Chromatography (FPLC) on A ¨kta Purifier
System (GE HealthCare) at 4uC. Cell pellet (4 g) was suspended in
40 mL of buffer A (Tris HCl 50 mM pH 7.5) and stirred for
30 min. Cells were disrupted by sonication (12 pulses of 10 sec,
with intervals of 1 min off) in presence of 0.2 mg mL
21 lysozyme
(Sigma Aldrich), and the clarified supernatant (48,000 g for 30 min
in all cases) was further treated with 1% (wt/vol) streptomycin
sulfate (Sigma-Aldrich). The latter supernatant was treated with
2.5 M ammonium sulfate and the resulting precipitate was
suspended in 40 mL of buffer A (crude extract). The crude extract
was loaded on a Q-Sepharose Fast Flow anion exchange column
(GE Healthcare) equilibrated with buffer A. Adsorbed material
was eluted with 0% to 50% linear gradient of Tris HCl 50 mM
NaCl 1 M pH 7.5 (buffer B) at 1 mL min
21 flow rate. Fractions
containing MtPRS, as inferred by 12% SDS-PAGE polyacrilamide
gel electrophoresis stained with Coomassie Brilliant Blue [32],
were pooled, concentrated and loaded on a Superdex 200 size
exclusion column (GE Healthcare) previously equilibrated with
buffer A. Proteins were eluted in isocratic conditions and fractions
containing MtPRS were loaded on a Mono Q HR 16/10 anion
exchange column (GE Healthcare) equilibrated with buffer A.
Proteins were eluted with 0% to 100% linear gradient of buffer B,
at 1 mL min
21 flow rate (Table 1). Homogeneous MtPRS eluted
at approximately 430 mM NaCl (Figure 2A). Fractions contain-
ing homogeneous MtPRS were pooled, dialyzed against buffer A,
concentrated, and stored at 280uC up to 7 months without any
loss of enzyme activity.
MtPRS Identification by Mass Spectrometry
LC-MS/MS peptide mapping experiments were performed to
confirm the identity of MtPRS samples. Briefly, the purified
samples were digested with trypsin using a protocol adapted from
[33], and the digested peptides were chromatographically sepa-
rated (Kinetex 2.6 mm C18 core-shell particles - Phenomenex,
Inc.) using a nanoLC Ultra system (nanoLC Ultra 1D plus,
Eksigent, USA) connected to a LTQ-Orbitrap hybrid mass
spectrometer (Thermo Electron Corporation, San Jose, CA).
The chromatographic method used a flow rate of 300 nL min
21
with a step gradient from mobile phase A containing 0.1% formic
acid in water to mobile phase B containing 0.1% formic acid in
acetonitrile (0–2% B over 5 min; 2–10% B over 3 min; 10–60% B
over 60 min; 60–80% B over 2 min; 80% B isocratic for 10 min;
80–2% B over 2 min; and 2% B isocratic for 8 min). MS/MS
fragmentation was performed using collision-induced dissociation
(CID) with an activation Q of 0.250, an activation time of 30.0 ms,
35% of normalized collision energy, and an isolation width of
1.0 Da. LC-MS/MS data were compared with theoretical MS/
M. tuberculosis PRPP Synthase
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tuberculosis H37Rv proteome (ftp://ftp.ncbi.nih.gov/genomes).
Determination of MtPRS Subunit Molecular Mass
Purified MtPRS samples were desalted, reconstituted in
methanol 50%/formic acid 1% and directly injected into an
IonMax electrospray ion source. The electrospray source param-
eters were as follows: positive ion mode, 5 kV of applied voltage to
the electrospray source, 37.6 V of capillary voltage, 310uCo f
capillary temperature, and 109 V of tube lens voltage. Full spectra
(770–2000 m/z range) were collected during 20 min on a Thermo
Orbitrap Discovery XL in profile mode at a nominal resolution r
=30,000 at m/z 400 using FT automatic gain control target value
of 1,000,000 charges. The average spectrum was processed with
the software MagTran [34] for charge state deconvolution.
MtPRS Quaternary Structure Assessment by Cross-linking
Studies
Cross-linking studies of the protein’s oligomeric states were
performed as described by Fadouloglou et al. [35], using
crystallization supports with 120 mL of 25% (v/v) glutaraldehyde
acidified with HCl in the reservoir. A cover slip was used to seal
the reservoir, containing a 10 mL drop of protein suspension
(0.3 mg mL
21 homogeneous recombinant MtPRS in buffer A) in
its apo form and incubated with Pi 50 mM, both in presence and
absence of ATP 5 mM, R5P 5 mM, and ADP 5 mM. The plates
were incubated at 30uC for different time intervals and protein
drops were subsequently analyzed by 12% SDS-PAGE.
MtPRS Activity Assays
All chemicals were purchased from Sigma Aldrich. All enzyme
activity assays were performed in triplicate. MtPRS activity was
measured by a coupled continuous spectrophotometric assay in
quartz cuvettes using a UV-visible Shimadzu spectrophotometer
UV2550 equipped with a temperature-controlled cuvette holder.
MtPRS reaction (ATP + R5P R PRPP + AMP) was coupled to M.
tuberculosis orotate phosphoribosyltransferase (MtOPRT, EC
2.4.2.10) forward reaction (OA + PRPP R OMP + PPi), in which
PRPP synthesis can be monitored by the decrease in orotate (OA)
concentration at 295 nm, for 60 sec at 25uC, using an extinction
coefficient value of 3950 M
21cm
21 [36], when ATP was the
diphosphoril group donor of the reaction catalyzed by MtPRS.
When GTP, CTP and UTP were used as substrates for MtPRS
enzyme activity measurements, the decrease in OA concentration
was monitored at 303 nm, for 60 sec at 25uC, using an extinction
coefficient of 2200 M
21cm
21 [37] due to strong absorption of
these nucleosides triphosphate at 295 nm. Homogeneous recom-
binant MtOPRT was obtained as described elsewhere [38].
Coupled assay conditions so as the indicator enzyme (MtOPRT)
did not limit the primary reaction (MtPRS) were employed
according to [39] and [40]. The reaction mixture (500 mL)
contained 1.8 U MtOPRT, 300 mM OA, 20 mM MgCl2, in Tris
HCl 50 mM pH 8.0. Reaction was started by addition of MtPRS
(0.24–1.2 mM). One unit of MtPRS is defined as the amount of
enzyme necessary to convert 1 mmol of R5P to PRPP per min.
Effect of Pi over MtPRS activity was assessed by varying Pi
concentration (10–50 mM) in the reaction conditions described
above.
Figure 2. A) MtPRS purification steps. Lane 1: Protein Marker – Fermentas; lane 2: crude extract; lane 3: sample loaded on Q-Sepharose; lane 4:
sample eluted from Q-Sepharose; lane 5: sample eluted from Superdex 200; lane 6: protein fraction eluted from Mono Q HR anion exchange step
showing homogeneous recombinant MtPRS (approximately 35 kDa). B) Determination of MtPRS molecular mass by mass spectrometry analysis.
Deconvoluted spectra of MtPRS resulted in a peak corresponding to the molecular mass of 35,345 Da. C) ESI-FTMS spectra showing the charge
distribution obtained for MtPRS, spanning from charge state 25+ to 45+.
doi:10.1371/journal.pone.0039245.g002
Table 1. Purification of MtPRS from 4 g of wet cell paste of E. coli BL21(DE3) host cells.
Purification step Total protein (mg)
Specific activity
(U mg
21) Total enzyme activity (U) Yield % Purification fold
crude extract 524 0.028 145 100 1
Q-Sepharose FF 19.6 0.518 10.16 7 18.5
Superdex 200 19 0.220 4.17 2.8 7.9
MonoQ 16/10 3.5 1.16 4.06 2.8 41.4
doi:10.1371/journal.pone.0039245.t001
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app and Vmax
app, were
determined by fitting the data for each substrate pairs to Henri-
Michaelis-Menten equation, Eq. (1) [41], in which v, Vmax,[ S],
and KM represent, respectively, steady-state reaction rate, maxi-
mum reaction rate, substrate concentration, and Henri-Michaelis-
Menten constant for substrate S. The kcat values and substrate
inhibition constant (Ki) were calculated, respectively, from Eq. (2)
[42] and Eq. (3) [41]; in which kcat and [E]t correspond to,
respectively, catalytic constant, or turnover number, and total
enzyme concentration, for Eq. (2). For Eq. (3), Ki represents the
dissociation constant for the inhibitory complex, and the
remaining variables are as for Eq. (1). Data analysis was
performed using SigmaPlot 10 Software.
v~Vmax½S =KMz½S ð 1Þ
Vmax~kcat½E t ð2Þ
v~Vmax½S =KMz½S (1z½S =Ki) ð3Þ
Inhibition Assays
Inhibition assays were performed at fixed-saturating concentra-
tions of R5P (60 mM) and ATP (300 mM), in either absence or
presence of varied concentrations of ADP (20 mM to 1.5 mM),
GDP (500 mM to 5 mM) or UMP (1 mM to 12 mM). Reaction
was started by addition of 0.24 mM MtPRS, under assay
conditions described above for substrate pair ATP/R5P. All
measurements were performed in triplicate. The concentration of
inhibitor required to reduce the fractional enzyme activity to half
of its initial value in the absence of inhibitor (IC50) was obtained
from fitting the data to Eq. (4) for partial inhibition [41], in which
y is the fractional activity of the enzyme in the presence of inhibitor
at concentration [I]; y(max) is the maximum value of y observed at
[I] =0; and ymin is the minimum limiting value of y at high
inhibitor concentrations.
y~
ymax{ymin
1z
½I 
IC50
zymin ð4Þ
Intrinsic Tryptophan Fluorescence (ITF) Spectroscopy
Intrinsic tryptophan fluorescence titration was carried out to
assess binary complex formation at equilibrium between MtPRS
and either substrate(s) or product(s) at 25uC [43]. All substrates
(R5P, ATP, GTP, UTP and CTP), products (AMP and PRPP)
and the enzyme were dissolved in buffer A containing MgCl2
20 mM. Fluorescence titrations were performed by making
microliter additions of substrates and products at varying stock
concentrations to 1 mL of MtPRS 3 mM, with a maximum
dilution of 6%. Ligand concentration ranges were as follow: R5P
0.99–126.83 mM; ATP 0.9–169.65 mM; GTP 0.9–309.24 mM;
UTP 0.9–389.25 mM; CTP 0.9–389.25 mM; AMP 0.99–
389.25 mM; and PRPP 0.99–389.25 mM. After each ligand
titration, the mixture was stirred for 3 minutes to ensure
equilibrium binding prior to ITF measurements. Measurements
of ITF of MtPRS employed excitation wavelength values of
292 nm (R5P) and 295 nm (PRPP, AMP, ATP, GTP, UTP and
CTP), and the emission wavelength ranged from 300 nm to
400 nm (maximum MtPRS lEM=336 nm). In the binding
experiments, different slits for, respectively, the excitation and
emission wavelengths were employed: 1.5 nm and 5 nm for R5P,
1.5 nm and 10 nm for binding of ATP, GTP, UTP and CTP, and
1.5 nm and 10 nm for the products AMP and PRPP. Control
experiments were performed in the same conditions in the absence
of MtPRS to verify any inner filter effect, and the values found in
the control experiments were subtracted from those obtained in
the presence of the enzyme. No corrections for effects of protein
dilution on ITF upon addition of buffer A containing MgCl2
20 mM to MtPRS were necessary. Data from equilibrium
fluorescence spectroscopy were fitted to Eq. (5) for hyperbolic
binding isotherms, in which F is the observed fluorescence signal;
Fmax is the maximal fluorescence intensity; and KD represents the
dissociation constant for binding of substrate and/or product to
MtPRS. Sigmoidal binding data were fitted Eq. (6) [44], in which
F is the observed fluorescence signal, Fmax is the maximal
fluorescence intensity, n is the Hill coefficient, and K’ is a constant
comprising interaction factors and the intrinsic dissociation
constant [42].
F
Fmax
~
FmaxS
KDzS
ð5Þ
F
Fmax
~
An
K
0zAn ð6Þ
Results
Cloning, Expression and Purification of Recombinant
MtPRS
Automated DNA sequencing confirmed the identity and
integrity of the pET-23a(+)::prsA construct. Recombinant MtPRS
protein was purified to homogeneity (Figure 2A) by a three-step
chromatographic protocol, with 2.8% yield and approximately 41
fold purification (Table 1). Desorption of recombinant MtPRS
from Q-Sepharose Fast Flow anion exchange column occurred at
approximately 390 mM salt concentration, with removal of
substantial amount of contaminants from the total protein sample.
Salt removal after size exclusion step led to an activity loss that was
reverted after homogeneous MtPRS elution from Mono Q HR at
430 mM salt concentration. Identity of recombinant MtPRS was
assigned by LC-MS/MS peptide mapping experiments, with
coverage of 61% of its primary sequence.
Mass Spectrometry Analyses
LC-MS/MS peptide mapping experiments. Apparently
homogeneous MtPRS samples were desalted, digested with
trypsin, and the peptide mixtures subjected to LC-MS/MS
analysis as described in the Methods section. 188 spectra were
obtained and identified with 27 different peptides derived from the
trypsin digestion of the MtPRS protein. These peptides covered
61% of the MtPRS sequence.
Molecular mass determination by mass
spectrometry. The spectra of intact MtPRS samples were
recorded with the Orbitrap analyzer for molecular mass determi-
nation as described in the Methods section. Peaks corresponding
to different charge states spanning from 25+ to the multiple charge
state 45+ were detected. From the deconvoluted spectra, a value of
35,345 Da was determined for the average molecular mass of
M. tuberculosis PRPP Synthase
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terminal methionine (theoretical subunit molecular mass of
35,477.47 Da with methionine and 35,346.28 without methionine)
(Figure 2B). As the value for subunit molecular mass of E. coli
PRS is 34,218.2, the mass spectrometry analysis also demonstrates
that the homogeneous protein is indeed recombinant MtPRS.
MtPRS Quaternary Structure Assignment
MtPRS quaternary structure could not be assigned by analytical
HPLC gel filtration chromatography due to formation of protein
aggregates under the experimental conditions described elsewhere
[45]. Cross-linking experiments of apo MtPRS were thus pursued
and indicates that there is a shift from monomeric, intermediate
multi oligomeric states, to predominantly hexameric forms
(approximately 220 kDa) after 45 min incubation time in the
absence of Pi (Figure 3A, lanes 1, 3–5). Intermediate oligomers,
mostly dimers (,70 kDa), trimers (,100 kDa) and tetramers
(,150 kDa) could also be visualized on Coomassie Brilliant Blue
stained gels. Although the presence of Pi 50 mM did not change
this oligomerization profile, it appears to have delayed the shift of
MtPRS to hexameric forms (Figure 3A, lanes 6–11). Pre-
incubation with R5P 5 mM in either absence or presence of Pi
50 mM appears to have no noticeable effects on shifting the
oligomeric states of MtPRS (Figure 3B) as the profiles are similar
to the apo form of MtPRS (Figure 3A). Pre-incubation with ATP
5 mM seems to stabilize MtPRS dimeric state (Figure 3C),
whereas pre-incubation with ADP 5 mM suggests that there is an
increase in the tetrameric state of MtPRS over time (Figure 3D),
both in the absence and presence of Pi 50 mM.
Enzyme Activity, Substrate Specificity and Inhibition
Assays
MtPRS enzyme activity could be detected in the absence of Pi,
and in the presence of varying concentrations of ATP dipho-
sphoryl group donor at fixed 60 mM of R5P (Figure 4A). When
substrate ATP was fixed at saturating concentration (300 mM) and
enzyme activity measurements at varying R5P concentrations
were carried out, substrate inhibition was observed at R5P
concentration values larger than 60 mM( Figure 4B). Addition of
10–50 mM of Pi to the assay mixtures abrogated MtPRS enzyme
activity detection due to inhibition of coupled enzyme MtOPRT
(data not shown), likely due to chelating effect of PO4
32 anions on
Mg
2+ cations [46]. As Mg
2+NPRPP is the true substrate of
MtOPRT [38], addition of Pi into the reaction mixture would
result in no formation of the true substrate and ensuing lack of
activity of MtOPRT coupled enzyme. Accordingly, all MtPRS
enzyme activity assays henceforth described were carried out in
the absence of Pi.
MtPRS enzyme activity could be detected when, under the
same experimental conditions, the ATP diphosphoryl group donor
was replaced with either purine (GTP) or pyrimidine (CTP and
UTP) nucleoside 59-triphosphates (Figure 5). Although the values
for the catalytic rate constants (kcat) of GTP, UTP and CTP are
lower than the value for ATP, the apparent overall dissociation
constant (KM) values are somewhat similar (Table 2). The lower
kcat values and similar KM values result in lower values for the
specificity constant (kcat/KM) of GTP, UTP and CTP in
comparison to ATP (Table 2). These results indicate that MtPRS
has broad substrate specificity being able to use ATP, GTP, CTP
and UTP as diphosphoryl group donors.
Addition of both ADP (Figure 6A) and GDP (Figure 6B)t o
MtPRS reaction mixture (ATP and R5P fixed at, respectively,
300 mM and 60 mM, under assay conditions described in the
Methods section) resulted in partial inhibition of enzyme activity.
The data on partial enzyme inhibition were fitted to Eq. (4),
yielding IC50 values of, respectively, 0.07 (60.01) mM and 0.9
(60.1) mM for ADP and GDP. Addition UMP to the reaction
mixture also resulted in partial inhibition of MtPRS, and data
fitting to Eq. (4) yielded an IC50 value of 3.0 (60.8) mM
(Figure 6C).
To ascertain whether or not these experimental data were due
to effects on MtPRS activity and not on MtOPRT coupled
enzyme, measurements of activity of the latter enzyme were
performed in the presence of the diphosphoryl group donors
(ATP, GTP, CTP, and UTP), and nucleoside diphosphate or
monophosphate inhibitors (ADP, GDP and UMP). The presence
of these compounds in the assay mixtures employed in the coupled
assays did not have any effect on MtOPRT enzyme activity to any
extent (data not shown). Accordingly, the effects of the alternative
diphosphoryl group donors, or nucleoside 59-diphosphate or
monophosphate inhibitors, were solely due to changes in MtPRS
enzyme activity.
ITF Spectroscopy
Binary complex formation between substrates (R5P, ATP,
GTP) or products (AMP, PRPP) and MtPRS was assessed by
equilibrium fluorescence spectroscopy to ascertain the order (if
any) of addition of these chemical compounds. Titration of MtPRS
with R5P, ATP and GTP were hyperbolic (Figure 7A). These
data were thus fitted to Eq. (5), yielding KD values of 61 (63) mM
for R5P, 18 (62) mM for ATP, and 21 (62) mM for GTP.
Titration of MtPRS with AMP product was sigmoidal (Figure 7B),
and data fitting to Eq. (6) yielded a value of 109 (63) mM for K’.
There was no intrinsic protein fluorescence change upon PRPP
binding to MtPRS, suggesting that PRPP cannot bind to free
enzyme. Binding experiments were also carried out in an attempt
to determine whether or not there is binary complex formation
between MtPRS and the alternative pyrimidine substrates UTP
and CTP, which can also substitute for ATP as diphosphoryl
group donors. No change in protein fluorescence could be
detected upon titration of MtPRS enzyme with UTP and CTP.
Discussion
Recently, Alderwick and co-workers [30] and Lucarelli and co-
workers [31] have also reported biochemical characterization of
MtPRS. Both reported protocols for cloning and purification of
recombinant MtPRS are significantly different from the one
described herein, since MtPRS reported here was produced as a
non-His-tagged protein. Although many protocols use histidine
tags to facilitate protein purification by the nickel-affinity
chromatography strategy, adding histidine tags may alter the
protein structure and the biological activity [47,48]. We have thus
deemed appropriate to make efforts to produce recombinant
MtPRS without any fusion partner to avoid any possible effect that
the latter may have on the former. Notwithstanding, it should be
pointed out that steady-state kinetics results were shown by
Lucarelli and co-workers [31] to be quite similar for His-tagged
MtPRS as compared to MtPRS treated with protease for removal
of the N-terminal His-tag fusion partner. The three-step
chromatographic purification protocol of recombinant MtPRS
here described yielded 3.5 mg of homogenous protein from 4 g of
wet cell paste (Figure 2A and Table 1). Recombinant MtPRS
protein was stable at 280uC in the absence of additives. However,
homogeneous MtPRS could not be concentrated above 1 mg
mL
21 in Tris HCl 50 mM pH 7.5 without precipitation, and
activity of precipitated protein could not be recovered. Interest-
ingly, Alderwick and co-workers [30] showed that recombinant C-
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39245Figure 3. MtPRS quaternary structure assignment by glutaraldehyde cross-linking experiments. Incubation times (numbers in black) are
shown at the bottom of each lane. Underlined incubation times indicate the presence of 50 mM Pi in the reaction mixtures. Lane numbers are in
white in a solid black background. M: Page Ruler Marker (Fermentas). A) Apo MtPRS. B) MtPRS incubated with R5P 5 mM. C) MtPRS incubated with
ATP 5 mM. D) MtPRS incubated with ADP 5 mM.
doi:10.1371/journal.pone.0039245.g003
Figure 4. Apparent steady-state kinetic constants for MtPRS, measured under standard assay conditions (Methods), for substrate
pair ATP/R5P. A) Varied ATP concentrations in presence of 60 mM R5P. B) Varied R5P concentrations in presence of saturating ATP (300 mM).
doi:10.1371/journal.pone.0039245.g004
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mL
21 in KH2PO4 buffer at pH 7.9 containing 150 mM NaCl,
1 mM DTT, 10% glycerol. It has been reported that addition of
ammonium sulfate or Mg
2+NATP was needed to preserve 20% of
MtPRS activity in 50 mM Tris-HCl pH 8.0 and 50 mM Hepes-
NaOH pH 8.0 buffers [31]. Lucarelli et al. [31] also reported that
full activity of MtPRS could be maintained with addition of
50 mM Pi. No loss of activity could be observed for MtPRS in Tris
HCl 50 mM pH 7.5 buffer for the protein preparation here
described. The possible explanations for these conflicting exper-
imental observations are rather elusive at the moment.
MtPRS quaternary structure could not be unequivocally
determined by size exclusion liquid chromatography, in agreement
with previous reports on PRS enzymes showing a tendency of
these proteins to exist in multiple aggregated states in solution,
ranging from dimeric to octameric quaternary structures [49,50].
Accordingly, the glutaraldehyde cross-linking method followed by
SDS-PAGE analysis [35] method was employed to determine the
MtPRS protein oligomerization state in solution. These data
suggest that recombinant MtPRS may adopt multiple oligomeric
states over time, in which the homo hexameric form is the
predominant quaternary structure for apo MtPRS after 45 min
incubation time in absence of Pi. Addition of 50 mM Pi to apo
MtPRS seems to delay this quaternary structure organization shift
from monomer to hexamer (Figure 3A). This apparent delay
might be related to Pi mediated stabilization of recombinant
MtPRS at alternative organization of quaternary states (in dimeric
or trimeric structures), as inorganic phosphate concentration of at
least 25 mM has been proposed as essential for PRS complete
stability [28]. Alternatively, binding of Pi to MtPRS may lead to
protection of lysine, tyrosine, histidine and arginine residues,
slowing the reaction of glutaraldehyde cross-linking over time.
However, whether the presence of Pi results in oligomeric state
stabilization or in reduction in cross-linking remains to be
established. Addition of R5P 5 mM appears to have no effect on
time-dependent shifting of MtPRS oligomeric states when
compared to its apo form (Figure 3B). Nevertheless, MtPRS
incubation with ATP 5 mM (Figure 3C) leads to a shift towards
dimeric quaternary structure with concomitant reduction in the
hexameric form, whereas incubation with ADP 5 mM
(Figure 3D) enhanced the MtPRS tetrameric organization. These
results are in agreement with previous reports on M. tuberculosis
Figure 5. Apparent steady-state kinetic constants for MtPRS, measured under standard assay conditions (Methods), for substrates
GTP, CTP and UTP, varied in the presence of fixed-saturating concentration of R5P (60 mM).
doi:10.1371/journal.pone.0039245.g005
Table 2. Apparent kinetic parameters for MtPRS reaction.
Substrate pair Kinetic parameters
KM (mM) Vmax (mmol
21 min
21 mg
21) kcat (s
21) kcat/KM (M
21 s
21) Ki (mM)
ATP/R5P 25 (64) 1.12 (60.03) 0.66 (60.02) 26 (64)610
3 –
R5P/ATP 14 (62) 1.41 (60.07) 0.83 (60.04) 59 (68)610
3 211 (628)
GTP/R5P* 37 (69) 0.237 (60.004) 0.140 (60.002) 3.8 (60.9)610
3 –
UTP/R5P* 52 (67) 0.264 (60.005) 0.155 (60.003) 3.0 (60.4)610
3 –
CTP/R5P* 26 (61) 0.111 (60.003) 0.065 (60.001) 2.5 (60.1)610
3 –
*Fixed R5P concentration at 60 mM.
doi:10.1371/journal.pone.0039245.t002
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velocity experiments in 50 mM KH2PO4 pH 7.9 buffer contain-
ing either R5P, ATP and ADP at the same concentrations
described here led to somewhat similar changes in oligomerization
states of MtPRS [30]. Namely, R5P has no effect and ATP
increased the hexameric species with concomitant decrease in
homodimeric state of MtPRS [30]. On the other hand, ADP has
been reported to affect the molar mass distribution increasing the
hexameric state with a concomitant reduction in trimeric species
[30]. This shift could be related to human PRS isoform 1 [11] and
B. subtilis [22] ADP binding site identification on the interface of
three subunits in the hexamer, a quaternary structure that might
be stabilized by the presence of ADP in solution. Interestingly,
analytical gel filtration results suggested that apo M. tuberculosis
PRS eluted as a single symmetrical peak consistent with the
hexameric state in phosphate buffer [31]. The data here presented
on glutaraldehyde cross-linking (Figure 3A) and elution of a single
peak from Superdex 200 size exclusion column (protein purifica-
tion protocol) suggest that MtPRS exists as a hexamer in Tris HCl
buffer and absence of ligands. Quaternary structure assignment of
PRS enzymes in solution remains ambiguous with varying results
in presence and absence of ligands [50]. It has been proposed that
ADP binding to an allosteric site of MtPRS induces stabilization of
an inactive, hexameric oligomeric species [30]. Further efforts
appear thus to be warranted to ascertain whether or not the
dynamic equilibrium of MtPRS has any bearing on enzyme
activity.
PRS enzyme activity is often assessed by radiochemical assays
with either [
14C]-R5P [30] or [c-
32P]-ATP detection
[11,25,49,51], by enzyme coupling with myokinase, pyruvate
kinase and lactate dehydrogenase [52], or by a recently developed
HPLC-based method that follows AMP formation [31]. Here we
present, to the best of our knowledge, a novel coupled continuous
spectrophotometric assay that measures the decrease in orotate
concentration catalyzed by MtOPRT in the presence of PRPP
formed in solution by MtPRS enzyme activity, a assay first
proposed as a suitable alternative to follow PRS activity in the late
709s, by Switzer and co-workers [28].
MtPRS-catalyzed PRPP formation could be measured in the
presence of R5P and ATP in absence of Pi (Figure 4A).
Interestingly, it has been reported that Pi is required for MtPRS
enzyme activity [30,31]. The reason for this discrepancy is not
apparent at the moment. Measurements of MtPRS enzyme
activity here presented were carried out in the complete absence
Figure 6. Inhibition of MtPRS enzyme activity by A) ADP; B) GDP; and C) UMP. MtPRS expressed as its fractional activity; and ADP, GDP and
UMP concentrations were plotted on log scale.
doi:10.1371/journal.pone.0039245.g006
Figure 7. A) Hyperbolic equilibrium binding of R5P, ATP and GTP to MtPRS assessed by ITF. B) Sigmoidal equilibrium binding of AMP to MtPRS
assessed by ITF.
doi:10.1371/journal.pone.0039245.g007
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activity measurements assessed in Tris HCl 50 mM MgCl2
20 mM pH 8.0, OA 300 mM, MtOPRT 1.8 U, and varied
concentrations of ATP and R5P. It is possible that an explanation
for this discrepancy may be attributed to coupled assay sensitivity,
allowing MtPRS activity detection even in absence of Pi.I n
addition, the steady-state kinetic constants for MtPRS enzyme
reported in this work (Table 2) are considerably distinct from
previous reports (Table 4) [30,31]. It could be argued that the
rather low values for the kinetic constants reported here are not
representative of MtPRS full activity, as it has being described that
lower Pi concentrations led to partial enzyme activity [30].
However, it appears more plausible that the rather low value for
the MtPRS catalytic constant is due to the limiting value for the
maximum velocity of the coupled enzyme (0.6 s
21) as reported
elsewhere [38]. Notwithstanding, the results presented here
demonstrate that Pi is not an obligatory requirement for MtPRS
catalytic activity. An interesting feature was identification of
substrate inhibition by R5P when it is varied in the presence of
saturating ATP concentration (Figure 4B), with Ki value of
211 mM. Substrate inhibition by R5P has been reported for rat
liver PRS [53], as well as for E. coli [54] and M. tuberculosis [30],
both in the presence of non-saturating Pi concentrations.
The dependence of MtPRS activity upon varying Mg
2+
concentrations could not be assessed as this cation is essential for
MtOPRT coupled enzyme activity [38]. We have thus fixed the
Mg
2+ concentration at 20 mM based on both the optimum
concentration for activity of MtOPRT (larger concentration values
are inhibitory) [38] and previously reported saturation curve for
the dependence of MtPRS activity on increasing Mg
2+ concen-
tration [31]. It has been shown that the enzyme requires free Mg
2+
as an activator and as Mg
2+NATP co-substrate, and that free Mg
2+
is likely to be an allosteric effector of the K-type enzyme model for
cooperativity [31].
Substrate specificity measurements showed that MtPRS can
accept GTP, CTP, and UTP, in addition to ATP, as diphosphoryl
group donors (Figure 5, Table 2), thereby showing broad
substrate specificity. Although the KM values are similar, the values
for the catalytic rate constants of GTP, CTP and UTP are lower
than ATP, MtPRS main substrate. S. typhimurium PRS, another
bacterial PRS, has been described as being specific for ATP,
although capable of using GTP, ITP, CTP and UTP as alternative
substrates to a lesser extent (3% of maximum reported activity
using ATP as substrate) [28].
The purine nucleoside diphosphates ADP and GDP were
reported as PRS allosteric inhibitors [23,25]. Under assay
conditions here described, both behave partial inhibitors with
IC50 values of, respectively, 0.0760.01 mM (Figure 6A) and
0.960.1 mM (Figure 6B). ADP has been shown to be a non-
competitive inhibitor of MtPRS with overall inhibition constant
Table 3. Comparison of biochemical data on M. tuberculosis PRS.
Reference Activity assay [Pi] dependency Cation dependency Quaternary structure
Alderwick, et al.
2011 [30]
R5P + ATP R PRPP + AMP (PRS)
AMP + ATP R 2ADP (MK)
ADP + PEP R 2 piruvate +2 ATP (PK)
2 piruvate +2 NADH +2H R 2 lactate +2 NAD
+
(LDH)
37uC
KH2PO4 50 mM pH 8.0
50 mM (full activation)
5 mM (partial activity)
Activation: Mn
2+ . Mg
2+
Inhibition: Ca
2+
Analytical ultracentrifugation:
E: trimer and hexamer (equilibrium);
E + R5P 5 mM: trimer and hexamer;
E + ATP 5 mM: Q hexamer q dimer;
E + ADP 5 mM: Qtrimer q hexamer.
Lucarelli, et al.
2010 [31]
HPLC, AMP formation
37uC
KH2PO4 50 mM pH 8.0
10–40 mM (59.7 U mg
21) Activation: Mn
2+ . Mg
2+
Inhibition: Cu
2+ . Fe
2+ .
Ca
2+
Size exclusion gel filtration:
Hexamer (220 KDa).
Breda, et al.
2012 (this work)
R5P + ATP R PRPP + AMP (MtPRS)
PRPP + OA R PPi + OMP (MtOPRT)
25uC
Tris HCl 50 mM pH 8.0
Activity without Pi
(1.16 U mg
21)
– Cross-linking:
E: monomer to hexamer;
E + R5P 5 mM: monomer to hexamer;
E + ATP 5 mM: Q hexamer q dimer;
E + ADP 5 mM: q tetramer.
doi:10.1371/journal.pone.0039245.t003
Table 4. Comparative of apparent kinetic parameters for MtPRS substrate pair ATP/R5P.
Reference Kinetic parameters
KM (mM) Vmax (mmol
21 min
21 mg
21) kcat (s
21) kcat/KM (M
21 s
21) Ki (mM)
R5P
Alderwick, et al. 2011 [30] 8.2 530 60.68 7430610
3 –
Lucarelli, et al. 2010 [31] 71 – 37.1 521610
3 –
Breda, et al. 2012 (this work) 14 (62) 1.41 (60.07) 0.83 (60.04) 59 (68)610
3 211 (628)
ATP
Alderwick, et al. 2011 [30] S0.5=62.65/n =1.68 601 – – –
Lucarelli, et al. 2010 [31] S0.5=260 (650)/n =1 – 34.6 (63) 133.1610
3 –
Breda, et al. 2012 (this work) 25 (64) 1.12 (60.03) 0.66 (60.02) 26 (64)610
3 –
doi:10.1371/journal.pone.0039245.t004
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it has been reported an IC50 value ranging from 0.26 mM (at
saturating ATP and non-saturating Pi concentrations) to 0.4 mM
(saturating ATP and saturating Pi concentrations) for ADP and an
IC50 larger than 5 mM for GDP inhibition of MtPRS activity in
the presence of Pi [31]. These results prompted the proposal of a
regulatory site to which both ADP inhibitor and Pi activator can
bind [31]. Accordingly, ADP binding to the regulatory site hinders
Pi binding resulting in inhibition of MtPRS enzyme activity [31].
In addition, the sigmoidal curve for ADP inhibition of MtPRS has
been shown to affect the maximum velocity only, without affecting
the value of K9 and the degree of cooperativity [31]. To evaluate if
MtPRS activity was responsive to pyrimidine regulation, the effect
of UMP titration upon standard activity assay (Methods) was
assessed (Figure 6C), which yielded an IC50 value of 3.0 (60.8)
mM. These findings seem to indicate that MtPRS activity is
regulated in response to M. tuberculosis energetic demand, being
more responsive to purine inhibition (ADP and GDP), although
variation in pyrimidine intermediates (UMP) could also regulate its
activity. The regulation of MtPRS enzyme activity by variations in
both purine and pyrimidine intermediates is in accordance with
the role of PRPP as a key intermediate in the metabolic pathways
for the synthesis and recycling of both purine and pyrimidine
nucleotides.
Hyperbolic binding isotherms determined from ITF measure-
ments indicated that substrates R5P (KD =61mM), ATP (KD
=18mM), and GTP (KD =21mM) can bind to free apo MtPRS
(Figure 7A). Dissociation constant values for ATP and GTP are
somewhat similar, an indicative that there might be no substrate
preference between these purine nucleosides 59-triphosphates,
which is in agreement with their similar KM values (Table 2).
Although the results of steady-state kinetic experiments have
shown that CTP and UTP can act as diphosphoryl group donors,
no change in IFT could be detected in the absence of R5P
substrate. These findings might suggest that binding of pyrimidine
nucleosides 59-triphosphate results in no change in tryptophan
fluorescence or that there is an alternative order of substrate
addition for pyrimidine nucleotides. No change in ITF could be
detected upon PRPP titration into free MtPRS. On the other
hand, AMP product showed hyperbolic variation of ITF upon
titration to free MtPRS, with K9 value of 109 mM and a Hill
coefficient value of 3.2 (Figure 7B), an indicative of positive
homotropic cooperativity. Further experiments of isothermal
titration calorimetry could be pursued to address the issue of
whether or not pyrimidine nucleotides are capable of binding to
free MtPRS.
Data on steady-state kinetics and equilibrium binary complex
formation suggest that the enzyme mechanism of MtPRS for
purine (ATP and GTP) diphosphoryl donors follows a random-
ordered substrate addition with ordered product dissociation, in
which PRPP is the first product to be released followed by purine
nucleoside monophosphate products (AMP or GMP) to yield free
enzyme for the next round of catalysis (Figure 8A). Although the
order of substrate addition can be proposed as it is based on solid
experimental evidence, the order of product release has to be
considered with caution. For instance, it is possible that PRPP
binding to free MtPRS enzyme results in no change in ITF, which
would imply in a random-order mechanism of product release.
Isothermal titration calorimetry can thus be used to address the
issue of whether or not PRPP is capable of binding to free MtPRS.
The enzyme mechanism for pyrimidine (UTP or CTP) diphos-
phate donors might obey an ordered mechanism of substrate
addition and product release; in which R5P binds to free enzyme
followed by the diphosphate donors, and PRPP release is followed
by pyrimidine nucleoside monophosphate products (UMP or
CMP) to yield free MtPRS (Figure 8B).
Considering their molecular and kinetic characterization, three
different classes of PRS enzymes have been described. Classifica-
tions of PRS proteins as belonging to Class I (also known as
‘‘Classical’’). Class II or Class III are based on specificity for
diphosphoryl donors, requirement of Pi for activity, allosteric
inhibition by purine ribonucleoside diphosphates, and oligomeric
states [23,25,31]. It has been proposed that there is also a
proportional relationship among KM, Vmax and PRS classes [25],
in which Class III enzymes have larger KM values for R5P and
ATP substrates, Class I with the lowest values, and Class II with
intermediate values [25]. The extent to which these criteria could
be used for classifying PRS enzymes are still not clear due to
limited number of representatives of Classes II and III PRSs [25].
MtPRS has approximately 41% identity to the three human
PRS isoforms, as well as to A. thaliana and spinach Class I enzymes
(isoforms 1 and 2). The degree of primary sequence conservation
drops to 18–23% when the M. tuberculosis sequence is compared to
Class II PRS enzymes from the latter two organisms (isoforms 3
and 4). As previously demonstrated [11,25,31], the amino acids
involved in substrate binding are the most conserved regions:
MtPRS Tyr88-Ser104 and Asp166-Arg169 for ATP binding, and
MtPRS Asp219-Thr227 for R5P binding. All amino acids involved
in ADP allosteric site, according to B. subtilis quaternary structure
[21], are conserved in MtPRS (Ser43, Arg45, Ser77, Ala78, Lys96,
His97, Arg98, Gly99, Arg100, Gln131, Asp139, His140, Ser306
and Phe311), in agreement with the inhibition data presented in
Figure 8. Proposed kinetic mechanisms for MtPRS using A) purine or B) pyrimidine 59-trisphosphate nucleotides, as diphosphoryl
group donors. Random order of addition for ATP or GTP and ordered addition of UTP or CTP substrates, with ordered release of products.
doi:10.1371/journal.pone.0039245.g008
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allosteric inhibitor of MtPRS [30,31]. Despite low amino acid
conservation, secondary structure prediction showed that homo-
trimeric spinach PRS isozyme 4 (a Class II enzyme) and
hexameric B. subtilis PRS (a Class I enzyme) have a similar folding
pattern [23]. No Class II PRS structure has been solved so far,
thus any inferences about amino acids substitution that might
account for this class broader substrate specificity are, based on
available structural data, somewhat speculative. PRS nucleotide
binding pocket is located in a wide cleft, and the secondary
structure elements might undergo conformational rearrangements
upon ligand binding to accommodate both purine and pyrimidine
bases, as well as properly positioning of amino acids side chains to
specifically hydrogen bond each diphosphoryl group donor.
The broad specificity for diphosphoryl group donors and
detection of enzyme activity in the absence of Pi would suggest that
MtPRS belongs to Class II PRS proteins. On the other hand, the
hexameric quaternary structure assembly, as suggested by cross-
linking experiments (Figure 3) would indicate that it belongs to
Class I PRS enzymes. In addition, allosteric inhibition by ADP
[30,31] (Figure 6A) would place MtPRS in Class I PRSs.
Accordingly, it has previously been suggested that MtPRS belongs
to Class I [30]. Further data are thus needed to classify MtPRS as
belonging to a particular family of PRS proteins.
It should be pointed out that the results here presented extend
previous studies on MtPRS [30,31]. To the best of our knowledge,
the results here presented are, along with S. typhimurium PRS data,
the first experimental evidence for a bacterial PRS enzyme that
can use both pyrimidine and purine nucleosides triphosphate as
diphosphoryl group donors since broad substrate specificity has
been described for plants only. In addition, this is the first report
on MtPRS enzyme mechanism for purine and pyrimidine
diphosphate donors. Current efforts are towards experimental
structure determination of MtPRS to provide a solid foundation
for the rational design of, hopefully, specific inhibitors of this
enzyme without affecting to a great extent the host PRS.
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